Acrux Limited (ARUXF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 1.13 Million AUD | -85.59% |
| 2023 | 7.87 Million AUD | 269.2% |
| 2022 | -4.65 Million AUD | 38.72% |
| 2021 | -7.59 Million AUD | -101.94% |
| 2020 | -3.75 Million AUD | 16.32% |
| 2019 | -4.49 Million AUD | -66.31% |
| 2018 | -2.7 Million AUD | -111.65% |
| 2017 | 23.18 Million AUD | -14.2% |
| 2016 | 27.02 Million AUD | 13.74% |
| 2015 | 23.75 Million AUD | -53.91% |
| 2014 | 51.54 Million AUD | 243.24% |
| 2013 | 15.01 Million AUD | 75.91% |
| 2012 | 8.53 Million AUD | -90.14% |
| 2011 | 86.59 Million AUD | 63.41% |
| 2010 | 52.99 Million AUD | 8052.46% |
| 2009 | 650 Thousand AUD | -83.08% |
| 2008 | 3.84 Million AUD | 32.59% |
| 2007 | 2.89 Million AUD | 460.35% |
| 2006 | 517 Thousand AUD | -80.93% |
| 2005 | 2.71 Million AUD | -16.96% |
| 2004 | 3.26 Million AUD | 337.46% |
| 2003 | 746.3 Thousand AUD | 36.33% |
| 2002 | 547.44 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | -4.67 Million AUD | -159.36% |
| 2024 Q2 | -2.27 Million AUD | -154.78% |
| 2024 Q4 | -2.21 Million AUD | 2.72% |
| 2023 Q4 | 4.15 Million AUD | 305.19% |
| 2023 Q2 | -2.02 Million AUD | 0.74% |
| 2023 FY | 7.87 Million AUD | 269.2% |
| 2022 FY | -4.65 Million AUD | 38.72% |
| 2022 Q4 | -2.04 Million AUD | 21.9% |
| 2022 Q2 | -2.61 Million AUD | 30.99% |
| 2021 Q4 | -3.78 Million AUD | 0.55% |
| 2021 FY | -7.59 Million AUD | -101.94% |
| 2021 Q2 | -3.8 Million AUD | 9.27% |
| 2020 FY | -3.75 Million AUD | 16.32% |
| 2020 Q4 | -4.19 Million AUD | -1062.16% |
| 2020 Q2 | 436 Thousand AUD | 115.34% |
| 2019 FY | -4.49 Million AUD | -66.31% |
| 2019 Q2 | 407 Thousand AUD | 208.53% |
| 2019 Q4 | -2.84 Million AUD | -798.28% |
| 2018 Q2 | 459 Thousand AUD | -93.76% |
| 2018 Q4 | -375 Thousand AUD | -181.7% |
| 2018 FY | -2.7 Million AUD | -111.65% |
| 2017 FY | 23.18 Million AUD | -14.2% |
| 2017 Q4 | 7.35 Million AUD | -44.34% |
| 2017 Q2 | 13.2 Million AUD | 40.42% |
| 2016 Q4 | 9.4 Million AUD | -43.79% |
| 2016 FY | 27.02 Million AUD | 13.74% |
| 2016 Q2 | 16.73 Million AUD | 55.25% |
| 2015 FY | 23.75 Million AUD | -53.91% |
| 2015 Q4 | 10.77 Million AUD | -17.26% |
| 2015 Q2 | 13.02 Million AUD | 34.77% |
| 2014 Q4 | 9.66 Million AUD | -76.77% |
| 2014 FY | 51.54 Million AUD | 243.24% |
| 2014 Q2 | 41.61 Million AUD | 271.69% |
| 2013 Q4 | 11.19 Million AUD | 176.56% |
| 2013 Q2 | 4.04 Million AUD | 0.0% |
| 2013 FY | 15.01 Million AUD | 75.91% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | 8.53 Million AUD | -90.14% |
| 2011 FY | 86.59 Million AUD | 63.41% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | 52.99 Million AUD | 8052.46% |
| 2009 FY | 650 Thousand AUD | -83.08% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | 3.84 Million AUD | 32.59% |
| 2007 FY | 2.89 Million AUD | 460.35% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | 517 Thousand AUD | -80.93% |
| 2005 FY | 2.71 Million AUD | -16.96% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | 3.26 Million AUD | 337.46% |
| 2003 FY | 746.3 Thousand AUD | 36.33% |
| 2002 FY | 547.44 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 92.439% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -36457.06% |
| SQZ Biotechnologies Company | 9.79 Million USD | 88.421% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 90.313% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.048% |
| Mesoblast Limited | -35.16 Million USD | 103.225% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 3420.644% |
| Genus plc | 178.7 Million USD | 99.365% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -176.474% |
| Marizyme, Inc. | 457.7 Thousand USD | -147.759% |
| ContraFect Corporation | -154 Thousand USD | 836.364% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 10409.091% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 2368.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1377.313% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1625.292% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 392.644% |
| MultiCell Technologies, Inc. | 49.32 USD | -2299170.073% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 97.184% |
| EV Biologics, Inc. | 48.9 Thousand USD | -2219.018% |
| Q BioMed Inc. | -8988.00 USD | 12716.822% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 95.987% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 7452.178% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.485% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1520.0% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 1012.669% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -1722.389% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 22999.838% |
| Arch Therapeutics, Inc. | -2439.00 USD | 46594.465% |
| IMV Inc. | -962.29 Thousand USD | 217.843% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -707.117% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1262.898% |
| GB Sciences, Inc. | -624.00 USD | 181830.769% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 1418.175% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.985% |
| Halberd Corporation | -208.00 USD | 545292.308% |
| Enzolytics Inc. | 30.7 Thousand USD | -3592.849% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 16.442% |
| SYBLEU INC | 11.69 Thousand USD | -9595.622% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -135.059% |
| argenx SE | 1.1 Billion USD | 99.898% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 104.396% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -83.678% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.723% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 12904.878% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 97.444% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 199.337% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -14.78% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 88.201% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 1452.431% |
| BioStem Technologies, Inc. | 15.42 Million USD | 92.648% |
| ONE Bio Corp. | 20.12 Million USD | 94.365% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 9681.749% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 2449.821% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -542.275% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -542.275% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 320.404% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 279.961% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 4010.345% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -151.976% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 454.922% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 75.391% |
| Bioxytran, Inc. | -8285.00 USD | 13787.387% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 404.021% |
| Neutra Corp. | 14.33 Thousand USD | -7810.708% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 1482.927% |
| PureTech Health plc | -1.6 Million USD | 170.742% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 213.26% |
| IXICO plc | 3.27 Million USD | 65.321% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 263.401% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 163.317% |
| CSL Limited | 7.7 Billion USD | 99.985% |
| Cellectis S.A. | 18 Thousand USD | -6200.0% |